Passage Bio (Passage Bio) Float Percentage Of Total Shares Outstanding : 83.33% (As of Jun. 09, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Passage Bio Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Passage Bio's float shares is 51.37 Mil. Passage Bio's total shares outstanding is 61.64 Mil. Passage Bio's float percentage of total shares outstanding is 83.33%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Passage Bio's Insider Ownership is 3.12%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Passage Bio's Institutional Ownership is 8.29%.

Passage Bio Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Passage Bio's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	51.37	/	61.64
	=	83.33%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Passage Bio (Passage Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Passage Bio Inc (NAS:PASG) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103

Website

https://www.passagebio.com

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Executives

Kathleen Borthwick	officer: SVP, Interim CFO	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Simona King	officer: Chief Financial Officer	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Dolan Sondhi	director	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Alexandros Fotopoulos	officer: Chief Technical Officer	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Sandip Kapadia	director	450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
William Chou	director, officer: Chief Executive Officer	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Monika Maria Toernsen	officer: Chief Commercial Officer	ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Michael E. Kamarck	director	C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Mark S Forman	officer: Chief Medical Officer	C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Bruce A Goldsmith	director, officer: CEO and President	C/O PASSAGE BIO, INC., TWO COMMERCE SQ, 2001 MARKET ST, 28TH FL, PHILADELPHIA PA 19103
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Brian Burkavage	officer: Controller	C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Derrell Porter	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080
Richard Steven Morris	officer: Chief Financial Officer	397 EAGLEVIEW BOULEVARD, EXTON PA 19341